BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 29th International Annual ...
Capricor Therapeutics has received an orphan drug designation for its drug aimed at potentially treating Becker Muscular Dystrophy. The biotechnology company said Tuesday that the Food and Drug ...
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics ...
University of Manchester scientists have mapped the mutations in the tiny protein chains that cause a subtype of muscular dystrophy. Published in the journal Nature Communications, the study provides ...
Presenters: Luca Bello, M.D., Ph.D, Associate Professor, Department of Neurosciences, DNS, University of Padova and Craig McDonald, M.D., Professor and Chair ...
– Company to host an Industry Forum to discuss the lived experience of Becker and clinical advancements featuring a leading neuromuscular disease expert and a patient advocate – Edgewise is sponsoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results